These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12932443)

  • 1. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress.
    Song Z; Fu DT; Chan YS; Leung S; Chung SS; Chung SK
    Mol Cell Neurosci; 2003 Aug; 23(4):638-47. PubMed ID: 12932443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galactosemic neuropathy in transgenic mice for human aldose reductase.
    Yagihashi S; Yamagishi S; Wada R; Sugimoto K; Baba M; Wong HG; Fujimoto J; Nishimura C; Kokai Y
    Diabetes; 1996 Jan; 45(1):56-9. PubMed ID: 8522060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.
    Yagihashi S; Yamagishi SI; Wada Ri R; Baba M; Hohman TC; Yabe-Nishimura C; Kokai Y
    Brain; 2001 Dec; 124(Pt 12):2448-58. PubMed ID: 11701599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase deficiency improves Wallerian degeneration and nerve regeneration in diabetic thy1-YFP mice.
    Chen YS; Chung SS; Chung SK
    J Neuropathol Exp Neurol; 2010 Mar; 69(3):294-305. PubMed ID: 20142761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
    Kamijo M; Basso M; Cherian PV; Hohman TC; Sima AA
    Diabetes Res Clin Pract; 1994 Sep; 25(2):117-29. PubMed ID: 7821191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
    Ho EC; Lam KS; Chen YS; Yip JC; Arvindakshan M; Yamagishi S; Yagihashi S; Oates PJ; Ellery CA; Chung SS; Chung SK
    Diabetes; 2006 Jul; 55(7):1946-53. PubMed ID: 16804062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of aldose reductase using neuronal cell culture and ligated rat sciatic nerve.
    Chandler CE; Miller LJ
    Metabolism; 1986 Apr; 35(4 Suppl 1):71-7. PubMed ID: 3083210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of aldose reductase and sorbitol dehydrogenase genes in Schwann cells isolated from rat: effects of high glucose and osmotic stress.
    Maekawa K; Tanimoto T; Okada S; Suzuki T; Suzuki T; Yabe-Nishimura C
    Brain Res Mol Brain Res; 2001 Mar; 87(2):251-6. PubMed ID: 11245928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Nrf2 Promotes Schwann Cell-Mediated Sciatic Nerve Recovery in Diabetic Peripheral Neuropathy.
    Tang W; Chen X; Liu H; Lv Q; Zou J; Shi Y; Liu Z
    Cell Physiol Biochem; 2018; 46(5):1879-1894. PubMed ID: 29719281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
    Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of polyol pathway to diabetes-induced oxidative stress.
    Chung SS; Ho EC; Lam KS; Chung SK
    J Am Soc Nephrol; 2003 Aug; 14(8 Suppl 3):S233-6. PubMed ID: 12874437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose reductase, still a compelling target for diabetic neuropathy.
    Oates PJ
    Curr Drug Targets; 2008 Jan; 9(1):14-36. PubMed ID: 18220710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sorbitol dehydrogenase deficiency on nerve conduction in experimental diabetic mice.
    Ng TF; Lee FK; Song ZT; Calcutt NA; Lee AY; Chung SS; Chung SK
    Diabetes; 1998 Jun; 47(6):961-6. PubMed ID: 9604875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycemia Promotes Schwann Cell De-differentiation and De-myelination via Sorbitol Accumulation and Igf1 Protein Down-regulation.
    Hao W; Tashiro S; Hasegawa T; Sato Y; Kobayashi T; Tando T; Katsuyama E; Fujie A; Watanabe R; Morita M; Miyamoto K; Morioka H; Nakamura M; Matsumoto M; Amizuka N; Toyama Y; Miyamoto T
    J Biol Chem; 2015 Jul; 290(28):17106-15. PubMed ID: 25998127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a novel aldose reductase inhibitor, TAT, and its effects on streptozotocin-induced diabetic neuropathy in rats.
    Inukai S; Agata M; Sato M; Naitou A; Matsukawa H; Goto M
    Jpn J Pharmacol; 1993 Mar; 61(3):221-7. PubMed ID: 8483299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.